Qualitative characteristics of HDL in young patients of an acute myocardial infarction

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 257-264

  Kavo, Anthula E ^a   Rallidis, Loukianos S ^b   Sakellaropoulos, George C ^a   Lehr, Stefan ^c   Hartwig, Sonja ^c   Eckel, Juergen ^c   Bozatzi, Polyxeni I ^a   Anastasiou Nana, Maria ^b   Tsikrika, Panagiota ^a   Kypreos, Kyriakos E ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

Apolipoprotein A I; Apolipoprotein C III; HDL quality; Premature myocardial infarction; Prognostic markers

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN M; ARYLDIALKYLPHOSPHATASE 1; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRON MICROSCOPY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OXIDATION REDUCTION POTENTIAL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AGE OF ONSET; ANALYSIS OF VARIANCE; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; EARLY DIAGNOSIS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GREECE; HUMANS; LIPOPROTEINS, HDL; MALE; MICROSCOPY, ELECTRON; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; PARTICLE SIZE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84155163888     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.10.017     Document Type: Article

References (44)

1. Gimbrone M.A. Vascular endothelium, hemodynamic forces, and atherogenesis. Am J Pathol 1999, 155:1-5.
2. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
3. Miller N.E., Thelle D.S., Forde O.H., Mjos O.D. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977, 1:965-968.
4. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
5. Shah P.K., Amin J. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 1992, 85:1279-1285.
6. Wilson P.W., Abbott R.D., Castelli W.P. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988, 8:737-741.
7. Forte T.M., Nichols A.V., Krauss R.M., Norum R.A. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest 1984, 74:1601-1613.
8. Gordon D.J., Rifkind B.M. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989, 321:1311-1316.
9. Sviridov D., Mukhamedova N., Remaley A.T., et al. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008, 15:52-62.
10. Frikke-Schmidt R., Nordestgaard B.G., Stene M.C., et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008, 299:2524-2532.
11. Roma P., Gregg R.E., Meng M.S., et al. In vivo metabolism of a mutant form of apolipoprotein A-I, apo A- IMilano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993, 91:1445-1452.
12. Roberts C.K., Ng C., Hama S., et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 2006, 101:1727-1732.
13. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-421.
15. Zheng Z.J., Croft J.B., Giles W.H., Mensah G.A. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158-2163.
16. Kypreos K.E. ABCA1 Promotes the de Novo Biogenesis of Apolipoprotein CIII-Containing HDL Particles in Vivo and Modulates the Severity of Apolipoprotein CIII-Induced Hypertriglyceridemia. Biochemistry 2008, 47:10491-10502.
17. Lehr S., Kotzka J., Avci H., et al. Effect of sterol regulatory element binding protein-1a on the mitochondrial protein pattern in human liver cells detected by 2D-DIGE. Biochemistry 2005, 44:5117-5128.
18. Bandoniene D., Murkovic M. The detection of radical scavenging compounds in crude extract of borage (Borago officinalis L.) by using an on-line HPLC-DPPH method. J Biochem Biophys Methods 2002, 53:45-49.
19. Okawa M., Kinjo J., Nohara T., Ono M. DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity of flavonoids obtained from some medicinal plants. Biol Pharm Bull 2001, 24:1202-1205.
20. Asztalos B.F., Schaefer E.J. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003, 91:12E-17E.
21. Monthony J.F., Wallace E.G., Allen D.M. A non-barbital buffer for immunoelectrophoresis and zone electrophoresis in agarose gels. Clin Chem 1978, 24:1825-1827.
22. Tsompanidi E.M., Brinkmeier M.S., Fotiadou E.H., et al. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2009, 208:3-9.
23. Schaefer E.J., Santos R.D., Asztalos B.F. Marked HDL deficiency and premature coronary heart disease. Curr Opin Lipidol 2010, 21:289-297.
24. Simon J.B., Boyer J.L. Production of lecithin: cholesterol acyltransferase by the isolated perfused rat liver. Biochim Biophys Acta 1970, 218:549-551.
25. Osuga T., Portman O.W. Origin and disappearance of plasma lecithin: cholesterol acyltransferase. Am J Physiol 1971, 220:735-741.
26. Soutar A.K., Garner C.W., Baker H.N., et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 1975, 14:3057-3064.
27. Santamarina-Fojo S., Hoeg J.M., Assmann G., Brewer H.B. The metabolic & molecular bases of inherited disease 2001, 2817-2834. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
28. Fournier J.A., Cabezon S., Cayuela A., et al. Long-term prognosis of patients having acute myocardial infarction when ≤40 years of age. Am J Cardiol 2004, 94:989-992.
29. Egred M., Viswanathan G., Davis G.K. Myocardial infarction in young adults. Postgrad Med J 2005, 81:741-745.
30. Zimmerman F.H., Cameron A., Fisher L.D., Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (coronary artery surgery study registry). J Am Coll Cardiol 1995, 26:654-661.
31. Panagiotakos D.B., Rallidis L.S., Pitsavos C., et al. Cigarette smoking and myocardial infarction in young men and women: a case-control study. Int J Cardiol 2007, 116:371-375.
32. Rallidis L.S., Gialeraki A., Komporozos C., et al. Role of methylenetetrahydrofolate reductase 677C→T polymorphism in the development of premature myocardial infarction. Atherosclerosis 2008, 200:115-120.
33. Schaefer E.J., Genest J.J., Ordovas J.M., et al. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis 1994, 108(Suppl):S41-S54.
34. McKeone B.J., Massey J.B., Knapp R.D., Pownall H.J., Apolipoproteins C.-I. C-II, and C-III: kinetics of association with model membranes and intermembrane transfer. Biochemistry 1988, 27:4500-4505.
35. Axler O., Ahnstrom J., Dahlback B., Apolipoprotein M associates to lipoproteins through its retained signal peptide. FEBS Lett 2008, 582:826-828.
36. Christoffersen C., Nielsen L.B., Axler O., et al. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
37. Navab M., Hama S.Y., Cooke C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000, 41:1481-1494.
38. Rodrigo L., Gil F., Hernandez A.F., et al. Purification and characterization of paraoxon hydrolase from rat liver. Biochem J 1997, 321(Pt 3):595-601.
39. Norum K.R., Gjone E. Familial serum-cholesterol esterification failure. A new inborn error of metabolism. Biochim Biophys Acta 1967, 144:698-700.
40. Gjone E., Norum K.R. Familial serum cholesterol ester deficiency. Clinical study of a patient with a new syndrome. Acta Med Scand 1968, 183:107-112.
41. Hamnstrom B., Gjone E., Norum K.R. Familial plasma lecithin: cholesterol acyltransferase deficiency. Br Med J 1969, 2:283-286.
42. Fruchart J.C., Sacks F., Hermans M.P., et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K-34K.
43. Harangi M., Mirdamadi H.Z., Seres I., et al. Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 2009, 153:190-198.
44. Nagila A., Permpongpaiboon T., Tantrarongroj S., et al. Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep 2009, 61:892-898.